The central challenge in tumor sequencing studies is to identify driver genes and pathways, investigate their functional relationships and nominate drug targets. The efficiency of these analyses, particularly for infrequently mutated genes, is compromised when patients carry different combinations of driver mutations.
and Beerenwinkel 8 proposed a non-standard likelihood ratio test but ended up with a severely misspecified null distribution. Mutex 11 has improved existing methods and used permutations to control false positive rates; however, its overly simple statistic warrants further improvement. In summary, most of the existing methods fail to correctly control for false positive rates and lack a criterion for selecting "optimal" MEGS.
Since some of these MEGS methods have been widely used in tumor sequencing projects, previous results may need to be interpreted with caution.
Ideally, an analytic framework for identifying MEGS shall have the following components. First, given a subset of m (m ≤ M) genes, a statistically powerful test is required to examine whether mutations in these m genes show ME. Second, it is crucial to determine whether any subset of the M genes is statistically significant after adjusting for multiple testing. Third, a model selection criterion is required to compare nested gene sets to select the "optimal" MEGS. An inappropriate criterion may falsely include genes into MEGS or exclude true genes from MEGS.
We developed a framework that fits all above requirements. We developed a likelihood ratio test (LRT) for testing ME and performed a multiple-path linear search together with permutations to test the global null hypothesis, i.e. the set of M genes does not contain MEGS of any size. When global null hypothesis was rejected, we proposed a model selection procedure based on permutations to identify "optimal" MEGS. All algorithms have been implemented in an R package called MEGSA (Mutually Exclusive Gene Set Analysis).
Extensive simulations demonstrated that MEGSA outperformed existing methods for de novo discovery and dramatically improved the accuracy of recovering exact MEGS, particularly for imbalanced MEGS. MEGSA can either be used for de novo discovery or by incorporating existing biological datasets (e.g. KEGG pathways and protein-protein interactions) to improve statistical power by reducing multiple testing, in spirit similar to MEMo 6 and Mutex 11 . We can also use MEGSA to expand well-established small MEGS with further improved power.
We applied MEGSA to analyze the whole exome sequencing data of 14 cancer types from TCGA. We identified multiple significant non-pairwise MEGS for breast cancer, low grade glioma, uterine corpus endometrial carcinoma skin cutaneous melanoma, head and neck squamous cell carcinoma and acute myeloid leukemia with important biological implications. Incorporating KEGG pathway data further identified 8 MEGS for breast cancer and 10 for low grade glioma. Although de novo discovery has lower power due to the high multiple testing burden, it has the potential to identify a more complete MEGS.
Incorporating external information may identify significant but likely incomplete oncogenic pathways. Thus, MEGSA shall be applied using these complimentary search strategies. We expect MEGSA to be useful for identifying oncogenic pathways and driver genes that would have been missed by frequency-based methods.
MEGSA is freely available at http://dceg.cancer.gov/tools/analysis/MEGSA.
Results

MEGSA: a framework for identifying mutually exclusive gene sets
We consider a binary mutation matrix A with N rows (cancer patients) and M columns (genes), where each row represents the mutational status for one patient and each column for one gene (Fig. 1A) . Let ik a denote the mutation status with a ik =1 if gene k is somatically mutated for patient i and a ik =0 otherwise. Here, a somatic mutation could be copy number alternations, non-synonymous point mutations or point mutations predicted to be deleterious. We consider non-synonymous point mutations in the manuscript. MEGSA has three components: (1) an efficient likelihood ratio test (LRT) for examining ME for a subset of genes; (2) a multiple-path linear search algorithm and a permutation framework to evaluate the global null hypothesis (GNH) and (3) a model selection procedure to identify the "optimal" MEGS.
A likelihood ratio statistic for testing mutual exclusivity
Given a subset of m (m ≤ M) genes and the binary mutation matrix (denoted as A 0 , a sub matrix of A), we describe a data generative model for MEGS. We assume that the m genes in the MEGS are completely mutually exclusive with coverage denoted as (2) For each sampled patient covered by the MEGS, we randomly choose a "mutated" gene according to 
Here, 0 = γ corresponds to the null hypothesis that the m genes are randomly mutated. 
Testing the global null hypothesis
Given a mutation matrix A with all M genes, it is crucial to test GNH that all genes are mutated independently. Suppose that we are interested in MEGS with no more than K genes. We have
combinations of genes to be tested, which equals to 2.0×10 11 if M=100 and K=8. The multiple testing burden increases with size exponentially when K < M/2. Importantly, the total multiple testing burden is dominated by the largest MEGS with K genes. When M=100 and K=8, the number of tests for MEGS with 8 genes account for 91.5% of total 2.0×10 11 tests while such proportion is only 8.0×10 -5 % for MEGS of 3 genes.
Intuitively, for the same nominal P-value of 10 -6 , a MEGS with 3 genes should be much more significant than the one with 8 genes. Thus, putative MEGS of different sizes must be differentially treated. Moreover, the statistic tests may be highly correlated; thus the Bonferroni correction is too conservative. We propose a permutation-based procedure to address these problems (Fig. 1C) . Note that permutations were performed by preserving the mutation frequency for each gene 7,11 .
Briefly, we first perform multiple test correction separately for MEGS of each size. For a given k (k ≤ K), we search all gene sets of size k to test for ME using our LRT and denote the minimum P-value as P k . The significance of P k, (denoted as Q k ) is estimated by permutations. Because we search for MEGS of different sizes, the overall statistic for testing GNH is θ =min(Q 2 ,⋯, Q K ), with significance evaluated by permutations.
Finding the minimum P-value P k by exhaustive search is computationally challenging even for a moderate k.
Thus, we implemented a multiple-path linear search algorithm to approximate P k (Methods).
Identifying optimal mutually exclusive gene sets using model selection
When GNH is rejected, we can use the multiple-path linear search algorithm to identify all significant putative MEGS (Methods). These putative MEGS may be nested. Consider two significant putative MEGS: MEGS1 has two genes (G 1 , G 2 ) with nominal P-value p 1 and MEGS2 has three genes (G 1 , G 2 , G 3 ) with nominal P-value p 2 based on LRT. Intuitively, if p 2 <<p 1 , we choose MEGS2 with three genes. However, a simple criterion p 2 < p 1 is too liberal and tend to include G 3 into MEGS even if G 3 is independent of (G 1 , G 2 ). This is because G 3 is chosen from the M-2 genes (G 3 , ⋯ , G M ) to form the strongest MEGS with G 1 and G 2 .
We addressed the problem in a statistical testing framework (Fig. 1D) . The null hypothesis is that none of the M-2 genes (G 3 , ⋯ , G M ) is mutually exclusive of (G 1 , G 2 ). We reject the null hypothesis (and thus choose MEGS2) if p 2 <p 0 with p 0 chosen to control false positive rate <5% based on permutations. Note that we keep the relationship between G 1 and G 2 unchanged and permute mutations only in (G 3 ,
independent of (G 1 , G 2 ), using p 0 as threshold will correctly choose MEGS1 with probability 95%.
Identifying mutually exclusive gene sets using three search strategies
We propose three complimentary strategies for searching MEGS using MEGSA, as illustrated in Fig. 2 . The first strategy is de novo discovery by directly applying MEGSA to all M genes ( Fig. 2A) . The advantage of de novo discovery is that it does not rely on any prior information and has the potential to identify a complete MEGS. However, de novo analyses may have low power because of heavy multiple testing burden.
MEGSA can also be applied by incorporating existing biological data, in spirit similar to MEMo 6 and Mutex 11 . MEMo searches for fully-connected sub graphs (called "cliques") using existing pathway and functional information (e.g. protein-protein interaction and gene coexpressoin) and analyzes each clique.
Mutex restricts search space so that genes in MEGS have a common downstream signaling target. Although MEGSA can be modified to perform similar search, we exemplify this approach by using the KEGG pathway database (Fig. 2B) . Briefly, we compare M genes with KEGG pathways and identify subsets (called modules) with more than 2 genes. We analyze each module using MEGSA and produce an overall P-value.
We choose significant modules by controlling FDR at 5%.
The third strategy is to search MEGS starting with a well-established small MEGS (e.g. EGFR and KRAS in lung cancer). We use our model selection procedure (Fig. 1D) to "grow" the MEGS until no gene can be included ( Fig. 2C ).
Evaluation on simulated cancer mutation data
Type-I error rate and power behavior of LRT
Since the LRT is the foundation for our algorithm, we first evaluated its type-I error rate and the power behavior for a fixed set of m genes. Under H 0 , LRT ~2 1 2 0 5 . 0 5 . 0 χ χ + asymptotically. Results based on 100,000 simulations verified that the P-values calculated based on the asymptotic distribution agreed well with the simulation-based P-values (Supplemental Table 1 ) for different combinations of parameters, including background mutation rate, sample size and the size of gene sets. The power of LRT increases with sample size and coverage and reduces with background mutation rates (Supplemental Fig. S1 ).
Comparison with other methods that detect mutually exclusive gene mutations
We compared the performance of MEGSA with the performances of existing methods including RME 12 , MEMo 6 , Dendrix 7 , LRT-SB 8 and Mutex 11 . MDPFinder 9 uses the same "weight" statistic as Dendrix but a more efficient computational method for searching MEGS; thus the comparative study does not include MDPFinder. A systematic comparison is very difficult for following reasons. Dendrix, RME and LRT-SB perform de novo analyses; MEMo uses existing biological data to reduce the search space; while MEGSA and Mutex can perform both analyses. In addition, for RME, Dendrix and LRT-SB, it is unclear how multiple testing was corrected. Mutex 11 compared the performances using receiver operating characteristic (ROC) analysis; however, it is unclear how false positives and false negatives were calculated. A more detailed summary and critique of these methods can be found in the Supplemental Note.
We empirically evaluated the null distribution of LRT-SB 8 . Simulation results show that the empirical distribution of LRT-SB deviates dramatically from the claimed null distribution N(0,1) (Supplemental Fig.   S2 ). See also the theoretical explanation in Supplemental note. MEMo derives a P-value for each "clique" and selects significant cliques by controlling FDR using these P-values. Controlling FDR requires P-values for null statistics to follow a uniform distribution U[0,1] 13 . However, our simulation results (under H 0 ) show that the P-values dramatically deviate from U[0,1] (Supplemental Fig. S3 ), suggesting that MEMo has incorrect false positive rates. In addition, MEMo does not select "optimal" MEGS sets appropriately and typically includes many false positives (Supplemental Fig. S4 and Supplemental Note). Thus, we excluded LRT-SB and MEMo from the comparison.
We simulated a mutation matrix for 54 genes in 500 samples. Among the 54 genes, mutations in 50 genes were randomly distributed. The 50 genes were classified into five groups; each group had 10 genes with mutation frequencies 1%, 5%, 10%, 20% or 30%. The simulated MEGS had 4 genes. The background mutation rates for these 4 genes were set as 1%. We simulated two types of MEGS ( Fig. 3A) . One had balanced mutation frequencies, i.e. all 4 genes in MEGS were mutated with the same frequency. The other had imbalanced mutation frequencies with ratio 3:1:1:1. Comparison was based on de novo analyses. The maximum size of MEGS was set as 8. The simulation results for MEGS with 3 genes are reported in 1 0
We first compared the performance of these methods as a "scoring" method without considering the statistical significance. Thus, we calculated the probability of choosing the true MEGS identified as the top candidate for each method. Simulation results show that MEGSA performs the best for all simulations and greatly improves existing methods particularly for imbalanced MEGS (Fig. 3B ). Of note, the performances are heavily impacted by the coverage of the MEGS for all methods. Dendrix has the worst performance and cannot identify the true MEGS even when the coverage is high. RME performs poorly for low coverage MEGS but reasonably well when coverage increases to 60% for balanced MEGS. Mutex outperforms RME and Dendrix.
Among Dendrix, RME, Mutex and MEGSA, only Mutex and MEGSA performed permutations to accurately evaluate overall significance (either family-wise error rate or FDR). Thus, we compared the performance of these two methods for statistically significant findings. For MEGSA, a significant finding was identified if its multiple testing corrected P-value < 0.05. For Mutex, a significant finding was identified if FDR<0.05. A simulation was considered successful if the detected top MEGS involved any pair of the 4 genes in the simulated MEGS. The power is calculated as the proportion of "successful" simulations ( Fig. 3C) . A much more rigorous criterion required that the top MEGS was statistically significant and identical to the simulated MEGS ( Fig. 3D ). We also calculated the average number of correctly identified genes (out of 4) and number of falsely identified genes (Supplemental Fig. S6 ). MEGSA outperforms Mutex in all comparisons.
Importantly, the performance of MEGSA is superior to that of Mutex for imbalanced MEGS, which are much more frequent than balanced MEGS in real data.
Although the three methods, RME, Mutex and MEGSA, have different performances, the probability of choosing the exact MEGS increases to one when sample sizes increase to infinity, an important statistical property called "consistency". However, the widely used Dendrix algorithm does not have this property and tends to include many false positive genes (See Supplemental Note for explanation). Here, we report more detailed simulation results for Dendrix, investigating the false positives in the selected top candidate. For low coverage MEGS with γ =40%, Dendrix chooses too many false positives, mostly in highly mutated genes (frequency π =30%) and lowly mutated genes (frequency π =1%). When coverage increases to 60%, Dendrix identified almost all genes in MEGS but still included many false positive genes. These simulation results suggest that, a high coverage MEGS identified by Dendrix may include multiple false positive genes.
Thus, MEGS identified by Dendrix may need to be interpreted with caution. Encouragingly, MEGSA has consistently high sensitivity and low false positive rates.
Finally, we investigated the power performance of MEGSA when input genes can be partitioned into L modules of equal sizes by incorporating pathway information. MEGSA was applied separately to each module to generate a module-wise P-value. A module was statistically significant if its P-value < 0.05/L based on the Bonferroni correction. Under the assumption that the true MEGS is completely contained in one of the modules, the power of detecting MEGS can be substantially improved compared to de novo analysis that simultaneously analyzes all genes (Supplemental Fig. S7 ).
Analysis of The Cancer Genome Atlas (TCGA) mutation data
We analyzed non-synonymous point somatic mutations identified by whole exome sequencing for 14 cancers in TCGA with data downloaded from the data portal (https://tcga-data.nci.nih.gov/tcga/). For cancer types included in the TumorPortal website (http://cancergenome.broadinstitute.org), we included candidate driver genes reported by the website 14 using MutsigCV 1 . Brain low grade glioma (LGG) is not reported in the TumorPortal website. Thus we identified candidate driver genes using MutsigCV 1 and included these genes into analysis. Sample sizes, numbers of selected genes and mutational frequencies are summarized in Supplemental Tables S2 and S3 . For each cancer type, we performed de novo analysis followed by the secondary analysis incorporating KEGG pathways. For de novo analysis, gene sets were considered statistically significant if P<0.05 after multiple testing based on 10,000 permutations. For KEGG-guided analysis, we derived a module-wise P-value for each module and declared significance by controlling FDR<0.05. Note that MEGS from pathway-guided analyses were discarded if they were a subset of any MEGS identified in de novo analyses.
De novo analyses identified non-pairwise MEGS for acute myeloid leukemia (LAML), LGG, breast invasive carcinoma (BRCA), skin cutaneous melanoma (SKCM), head and neck squamous cell carcinoma (HNSC) and uterine corpus endometrial carcinoma (UCEC). For other cancer types, de novo analysis only identified pair wise MEGS. Here, we report detailed results for BRCA and LAML. The complete results are summarized in Supplemental Table S4 .
Analysis results for BRCA
De novo analyses identified 10 significant but overlapping MEGS for BRCA with 989 patients. These MEGS involved 11 genes with TP53 involved in all MEGS (Fig. 4A ). We identified five MEGS with P<10 -4 ( Fig.   4B ). These MEGS were not reported by the BRCA article 15 using MEMo 6 that relies on functional data, emphasizing the necessity of de novo search.
The most significant MEGS has four genes (TP53, CDH1, GATA3 and MAP3K1) and covers 59.6% of patients. E-cadherin, encoded by CDH1, is important in epithelial-mesenchymal transition (EMT). Morever, GATA3, p53 and MAP3K1 are related to the expression of CDH1. Loss of p53 represses E-cadherin expression in vitro as a result of CDH1 promoter methylation 16 ; GATA3 expression is correlated with Ecadherin levels in breast cancer cells 17 ; and E-cadherin expression can be repressed by Snail/Slug following activation by the MAPK/ERK pathway 18 .
The largest MEGS has five genes TP53, AKT1, ARID1A, MED23 and TBL1XR1 (P=0.022) covering 40.4% of patients ( Fig.s 4C and 4D ). Of note, this MEGS is extremely imbalanced: all genes except TP53 are infrequently mutated with frequency 1-2% and could not be identified by other methods, consistent with the results of simulations. TBL1XR1 belongs to and regulates the core transcription repressor complexes NCoR/SMRT 19 , and p53 gene targets may be regulated by the SMRT in vitro in response to DNA damage 20 .
ARID1A encodes BAF250a, a component of the SWI/SNF chromatin-remodeling complex that directly interacts with p53 [21] [22] [23] [24] . Therefore, loss of ARID1A may have a similar effect as p53 deficiency. The mutual exclusivity between MED23 and other genes have not been reported previously. MED23 is a subunit of the mediator complex, a key regulator of gene expression and is required for Sp1 and ELK1-dependent transcriptional activation in response to activated Ras signaling [25] [26] [27] [28] . MED1 and MED17 directly interact with p53 28 , suggesting a possible connection between p53 and MED23 via the mediator complex. Also, MED23
interacts directly with the transcription factor ESX/ELF3 28 , which is downstream of AKT1 in the PI3K pathway. ESX-dependent transcription following activation by AKT is key for cell proliferation and survival.
In summary, these genes have key roles in chromatin remodeling (TBL1XR1 and ARID1A), gene expression regulation (MED23 and TP53), and signaling (AKT1), and likely regulate common set of gene targets downstream of the p53, PI3K and MAPK/ERK signaling pathways that are important for cell cycle control, survival and proliferation. Importantly, these infrequently mutated genes are unlikely to achieve high statistical significance using frequency-based driver gene test, e.g. MutSigCV 1 . In fact, in the BRCA article 15 , MED23 and ARID1A were not reported as significantly mutated while FOXA1 and CTCF were reported only as "near significance".
Because MutSigCV is highly sensitive to the choice of "Bagle" gene set for estimating the silent mutation rate, a very large sample size is required to replicate these findings. Given that TP53 is a well-established driver gene, the observed mutual exclusivity provides strong and independent evidence for establishing these genes' role as drivers.
Pathway-guided analysis identified 8 MEGS that were not detected by de novo analyses. Interestingly, we found that CBFB was mutually exclusive of ARID1A, MED23 and TP53. As described above, p53 can interact with ARID1A in the SWI/SNF chromatin remodeling complex via BRG1 (see Fig. 4D for SWI/SNF complex). The transcriptional coactivator CBFB is known to interact with the tumor suppressor RUNX1, the predominant RUNX family member in breast epithelial cells 29 . RUNX1 interacts with SWI/SNF via BRG1 30 , and act as transcriptional coactivator for p53 in response to DNA damage 31 . Thus, we propose that the loss of either one of these genes would be sufficient to lead to abnormal SWI/SNF complexes and dysregulation of chromatin-related epigenetics and gene expression leading to inhibition of apoptosis.
Breast cancer is highly heterogeneous with only two genes (TP53 and PIK3CA) with mutation frequencies greater than 15% (Supplemental Table S3 ). The majority of genes have mutation frequencies around 1-2%, making it difficult to identify MEGS. We successfully identified 10 significant MEGS based on de novo analyses and additional 8 guided by KEGG pathways. Other biological databases, e.g. functional data and Human Reference Network in MEMo 6 or the common downstream target database in Mutex 11 , could be used in the future to guide the search of MEGS.
Analysis results for LAML
Compared with other cancer types, AML genomes have the lowest somatic mutation rates 1 , with only 13 mutations in coding regions in average. Such a low overall (and also background) mutation rate suggests a good statistical power even with a small sample size according to our simulations (Supplemental Fig. S2 ).
In fact, de novo analyses identified 5 distinct but overlapping significant MEGS. These significant MEGS involve 9 genes with TP53 and FLT3 shared by 4 MEGS (Fig. 5A) . The pathway-guided search did not detect additional MEGS.
The most significant MEGS (Fig. 5B) has three genes NPM1, RUNX1 and TP53 (P<10 -4 ), which is a subset of the top MEGS (four genes and four fusions) reported by the TCGA LAML article 32 . We further tested the association of the mutations in these three genes and their combinations with survival, adjusting for age, stage and gender. Strikingly, the strongest association was detected for the MEGS (P=6.7×10 -4 , Fig. 5C . These results suggest that the mutual exclusivity between CEBPA and other genes is at least suspicious and requires independent replication.
The largest MEGS (Fig. 5D) has five genes FLT3, IDH2, KIT, NRAS and TP53 (P=0.0099), covering 55.1% of patients. This MEGS was not reported by the LAML article 32 . Fig. 5E describes important connections between function/pathways for the five gene products suggesting biological plausibility. FLT3 and KIT encode receptor tyrosine kinases upstream of the PI3K and MAPK/ERK signaling pathways, and NRAS is also part of MAPK/ERK. Mutations activating theses pathways or inactivating TP53 are common mechanisms that cancer cells use to proliferate and escape apoptosis 33 .
Interestingly, we discovered that IDH2 belongs to this MEGS. IDH2 encodes a mitochondrial enzyme, that converts isocitrate to α -ketoglutarate (αKG) in the tricarboxylic acid cycle and in this process produces the antioxidant nicotinamide adenine dinucleotide phosphate (NADPH), which is necessary to combat oxidative damage/stress 34, 35 . Mutant IDH2 is predicted to result in: depletion of α -KG; a decrease in NADPH;
production of 2-hydroxyglutarate (2-HG); and may elevate cytosolic reactive oxygen species (ROS) 36 .
Mutant IDH2 can result in epigenetic effects on gene transcription (including DNA hypermethylation and histone demethylation); while loss of p53 function can result in increased expression of DNA methyltransferase 1 (DNMT1) 16, 37 . Thus, a reasonable explanation for the observed mutual exclusivity between TP53 and IDH2 is that the loss of either protein activity may result in similar aberrant gene methylation patterns across the genome and dysregulated gene expression. We also suggest a further novel hypothesis. Depleted α -KG levels in IDH2 mutant cells may be replenished by the conversion of glutamate to α -KG in the mitochondria 38 . The provision of glutamate in the mitochrondria is regulated by p53 via expression of the enzyme glutaminase (GLS), which also regulates antioxidant defense function in cells by increasing reduced glutathione (GSH) levels 39 41, 42 . Thus IDH2 mutation may be sufficient to exclusively deregulate cell proliferation and survival processes important for AML development.
Discussion
We developed a powerful and flexible framework, MEGSA, for identifying mutually exclusive gene sets (MEGS). MEGSA outperforms existing methods for de novo analyses and greatly improves the capability of recovering the exact MEGS, particularly for highly imbalanced MEGS. The key components of MEGSA are a likelihood ratio test and a model selection procedure. Because likelihood ratio test is asymptotically most powerful, MEGSA is expected to be nearly optimal for de novo search. Our algorithms can be easily adapted to other methods that integrate with external information, e.g. MEMo and Mutex, to improve performance.
As an important contribution, we carefully examined the performance of existing methods. We concluded that many methods had incorrect false positive rates and poor performance for selecting optimal MEGS.
Importantly, mutual exclusivity analysis may help identify infrequently mutated driver genes, as we demonstrated in the TCGA BRCA data.
MEGSA can be further improved in several ways. First, MEGSA does not consider the extremely variable somatic mutation rates across patients. Including patients with very high mutation rate may increase the background mutation rate and thus decrease the statistical power. We are currently extending MEGSA by modeling patient-specific background mutation rates. Second, MEGSA uses a multiple-path search algorithm for computational consideration and may miss findings. The Markov Chain Monte Carlo (MCMC) or the genetic algorithm may address the issue.
In the current manuscript, we analyzed TCGA non-synonymous point mutations for the purpose of testing the MEGSA algorithm. We plan to extend the analysis to include somatic copy number aberrations (SCNAs), recurrent gene fusions 32 and epigenetic alternations. Moreover, it would be extremely interesting to restrict analysis to clonal point mutations carried by all cancer cells. Clonal mutations happen before the most recent common ancestor and are located early in the evolution tree of the tumor 43 ; thus clonal mutations are likely relevant for tumorigenesis. Focusing the analysis on clonal mutations, although technically challenging [44] [45] [46] , can substantially reduce the background mutation rates and consequently improve statistical power. More importantly, this refined analysis may better reveal oncogenic pathways related with tumorigenesis.
Methods
A likelihood ratio statistic for testing mutual exclusivity
Suppose that a MEGS has m genes with mutation matrix denoted as A 0 . We assume that the m genes are completely mutually exclusive. A MEGS is characterized by two parameters: the coverage 
The last equation holds because mutations are independent across genes. By the definition of coverage,
If the patient is not covered by the MEGS,
Furthermore,
(5)
Combining (1) 
We test 0 : 
Testing the global null hypothesis
Our algorithm for testing the global null hypothesis (GNH) has the following steps. (1) For k (k≤K), we search all gene sets of size k from M genes to test for ME using LRT and denote the minimum P-value as P k .
(2) We run T permutations, calculate the minimum LRT P-value P k (t) for permutation t and estimate the significance (denoted as Q k ) of the observed P k as the proportion of simulations with P k (t) smaller than the observed P k . Intuitively, Q k measures the significance when searching only for MEGS of size k. 
Identify statistically significant MEGS
Remember that we use θ =min(Q 2 ,⋯,Q K ) as the overall statistic for testing GNH. Once GNH is rejected at level α =0.05, we need to identify all combinations of genes that reach significance. First of all, based on permutations, we can identify a cut-off θ 1-α . In the multiple-path search algorithm described above, for each combination of k genes, we transform its nominal LRT P-value to Q based on permutations and declare this gene set as significant if Q<θ 1-α . This procedure may identify significant but nested putative MEGS. We designed a model selection procedure described in Fig. 1D to make a choice between nested models. the subset (called a module) of M genes (with mutation data) in the pathway. We eliminate duplicate modules or modules with less than 3 genes, and analyze each module using MEGSA to derive module-wise P-values. We control FDR<0.05 using these module-wise P-values to choose significant modules and identify optimal MEGS. (C) Expanding established small MEGS (G 1 , G2) by the model selection procedure described in Fig. 1D . 
